Seller record · Research vendor

Nexus Peptides

By Peptide Alliance, Editorial publisherRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 3 of 8 criteria. S1, prescriber requirement: No clinician evaluation is claimed anywhere on the site, and the terms sell every product for laboratory research use only. 2 more criteria also fail; see the table below.

At a glance

Nexus PeptidesResearch vendor

5/8criteria passed

Price: Printed on its own pages before sign-up
Sells: research peptides including BPC-157, CJC-1295, ipamorelin and MOTS-c, and 3 more
FDA letters: None on file

Visit Nexus Peptides See all eight dispositions

Research vendor. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A research peptide seller shipping from a Wyoming address and selling behind a researcher attestation. Its certificate archive links a batch report for each product, among them a triple-agonist vial whose report names the substance as retatrutide.

Operating entity No legal entity name appears in the footer, on the contact page, in the terms or in the privacy policy.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	FAIL	Nexus Peptides' terms privacy page
S2	Prescription gating	FAIL	Nexus Peptides' checkout
S3	Pharmacy identification	FAIL	Nexus Peptides' terms privacy page
S4	Compounding disclosure	PASS	Nexus Peptides' terms privacy page
S5	Analytical documentation	PASS	Nexus Peptides' certificate of analysis
S6	Business address	PASS	Nexus Peptides' contact page
S7	Price disclosure	PASS	Nexus Peptides' product page
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1FAILNo clinician evaluation is claimed anywhere on the site, and the terms sell every product for laboratory research use only.Source: Nexus Peptides' terms privacy page.

S2FAILA guest checkout collects billing details with no eligibility question, starting from the BPC-157 page at 179.99 dollars.Source: Nexus Peptides' checkout.

S3FAILNo pharmacy is named anywhere on the site, and the terms describe the seller as a supplier of research and laboratory material.Source: Nexus Peptides' terms privacy page.

S4PASSThe seller offers no compounded drug, and the terms state that the products are sold for research and laboratory use only and treat no disease.Source: Nexus Peptides' terms privacy page.

S5PASSA certificate archive links a batch report for each product from Analiza Bialek of Wroclaw, among them retatrutide batch RET-0426 at 99 percent purity, reachable with no login.Source: Nexus Peptides' certificate of analysis.

S6PASSThe contact page prints a street address in Sheridan, Wyoming, beside a Netherlands mobile number listed under a United States toll-free heading.Source: Nexus Peptides' contact page.

S7PASSThe BPC-157 page prints a range from 109.99 dollars through 179.99 dollars across two vial sizes, visible with no account.Source: Nexus Peptides' product page.

S8PASSNo FDA warning letter names the storefront, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: research peptides including BPC-157, CJC-1295, ipamorelin and MOTS-c, NAD+ injection vials, peptide vial packs, retatrutide, named on its batch certificate.

Other sellers of the same products

Who sells NAD+Who sells BPC-157 Who sells MOTS-c Who sells ipamorelin Who sells retatrutide

Visit Nexus Peptides

535 sellers pass S1, prescriber requirement

See all 535 on the S1 criterion page — 527 more than shown here.

This seller fails criteria a medical service must meet. The records above belong to sellers that pass S1; some are partner links, disclosed on their records.

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.